Vical Inc. (VICL)

[Tough_to_make_money]

Early PR.

SAN DIEGO, June 13, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference (Boston, June 16 - 20).

Dr. Mammen P. “Anza” Mammen, M.D. Vical’s Vice President, Clinical Vaccines, will present in the conference’s clinical virology session on June 20, 2016 at approximately 10:30 am. Trial results, including safety and efficacy endpoints, will be presented in the oral late-breaker presentation. The slides presented by Dr. Mammen will be available on Vical’s website after the presentation.

Looking at the charts and insider buying this just may be some exciting news to come!